Disposition and safety of omapatrilat in subjects with renal impairment

30 subjects with varying degrees of renal function, including normal (CLCR ≥80 mL/min/1.73 m², n=8), mild to moderate impairment (CLCR <80 to ≥30 mL/min/1.73 m², n=8), severe impairment (CLCR <30 mL/min/1.73 m², n=8), and subjects undergoing maintenance hemodialysis (n=6).

Oral omapatrilat 10 mg/day administered for 8 to 9 days.

Subjects with normal renal function (CLCR ≥80 mL/min/1.73 m²).

Pharmacokinetics (Cmax and AUC(0-T)) of omapatrilat and its metabolites.surrogate